Our Biopharmaceuticals businesses consist of five patient-centric, customer-facing business units. The business units are responsible for further clinical development and life-cycle management of promising new medicines that have achieved "proof of concept" in our labs. They also ensure that customer and patient needs inform the development of new medicines that can have the desired impact in the marketplace and on people's lives.
KEy MEDICINES
- Celebrex
- Chantix/ Champix
- Lipitor
- Lyrica
- Premarin
- Pristiq
- Toviaz
- Viagra
Primary Care provides more than a slate of high-value medicines. We also offer solutions that help health care professionals and providers do what they do best—roll back the tide of chronic, costly conditions one patient at a time and improve overall health. Pfizer's largest business unit, Primary Care, operates globally in markets including the U.S., Europe, Japan, Korea, Canada, Australia and New Zealand.
We lead with medicines to treat pain, high cholesterol, smoking cessation and other widespread conditions. Our pipeline includes molecules with potential in women's health, pain, cardiovascular disease, diabetes and Alzheimer's disease. Our goal is to be a valued partner in primary care for patients, health care providers and payers by delivering solutions that improve outcomes and overall health.
2010 Highlights
-
Approval of a pediatric indication for Lipitor in the European Union
-
Approval of Lyrica for neuropathic pain in Japan
-
Significant growth of Champix in Japan following consumer and physician education and a tobacco tax increase
-
FDA approval for 23 mg, higher dose Aricept for the treatment of moderate-to-severe Alzheimer's disease
-
Submission of response to approvable letter from the FDA on Pristiq application as a nonhormonal treatment for vasomotor symptoms related to menopause
KEy MEDICINES
- Benefix
- Enbrel
- Genotropin
- Geodon
- Prevnar 13
- Revatio
- Vfend
- Xalatan
- Zyvox
Specialty Care features a robust portfolio of market-leading medicines spanning 11 disease areas. We are leaders in vaccines and inflammation, two important areas of innovation and growth in biomedical science, and have a leading presence in helping doctors treat or prevent diseases ranging from pneumococcal disease in infants and young children and rheumatoid arthritis, to life-threatening infections, glaucoma and growth hormone deficiency.
For millions of the people we serve, our medicines keep difficult diseases well enough in check to let them enjoy their lives, earn a living and function in society. For others, our medicines and vaccines have a profound impact on patients' quality of life and survival for a range of serious diseases. Many of our patients face both the pain of a rare disease and the struggle to have the condition better recognized and understood. We share our deep knowledge of our disease areas with all of our customers—providers, patients and payers—and development partners to help ensure that people who can benefit from our medicines do so, and that people in search of new treatments for serious diseases have reason to be hopeful.
2010 Highlights
-
Prevenar 13 for pediatric use is gaining approval and has been launched in key markets around the world.
-
Maintained growth of Enbrel
-
Achieved six product line extension approvals
-
Completed acquisition of FoldRx, with lead candidate tafamidis
-
Geodon's adjunctive bipolar maintenance indication launched in the U.S.
-
MACUGEN has demonstrated efficacy in Phase III trials for diabetic macular edema.
-
Received CHMP positive opinion for Xiapex for Dupuytren's contracture
KEy MEDICINES
- Sutent
- Torisel
We investigate the complexities of cancer and discover and develop innovative treatment options to improve the outlook for cancer patients worldwide. Our oncology pipeline has both biologics and small molecule compounds in development, including several first-in-class treatment candidates. We have more than 100 clinical trials under way, searching for new options to treat sarcoma, melanoma and lung, prostate, breast, renal cell and various blood cancers. We also continue to seek new indications for approved drugs, such as Sutent, an oral multikinase inhibitor used to treat advanced/metastatic kidney cancer and imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Our scientists, working internally and with many alliances and partnerships, are among the leaders in the effort to develop therapies that focus on the personalized approach to treating cancer.
One example is crizotinib, a first-in-class compound that inhibits a tumor-specific protein called anaplastic lymphoma kinase, or ALK, for patients with ALK-positive advanced non-small cell lung cancer. Based on positive Phase I clinical trial results, crizotinib has advanced rapidly into Phase III trials. Pfizer expects to complete the new drug application submission for crizotinib in the U.S. in the first half of 2011.
2010 Highlights
-
Sutent has been approved in Europe for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression in adults.
-
Bosutinib has demonstrated improvement over imatinib in major molecular response rate at one year, a secondary endpoint, despite missing the primary endpoint of complete cytogenetic response rate at one year in patients with newly diagnosed chronic myeloid leukemia.
-
Axitinib has demonstrated significant extension in progression-free survival compared to sorafenib in a Phase III trial of patients with previously treated metastatic renal cell carcinoma.
KEy MEDICINES
- Enbrel
- Lipitor
- Lyrica
- Prevenar 13
- Viagra
- Norvasc
- Effexor
- Tazocin/Zosyn
- Protonix
- Relpax
In 2010 we closely reviewed the alignment and synergies between the Emerging Markets and Established Products business units and brought them together under single leadership.
In this way we aim to grow our market share in emerging markets, compete more effectively in developed markets, and pursue sustainable growth by gaining a broader portfolio of off-patent products. Through strategic business development and partnerships, we plan to enhance our capabilities in generic product development, low-cost manufacturing and high-volume regulatory processing.
Pfizer is a leading pharmaceutical company in the emerging markets, having posted strong double-digit growth in 2010 for several innovative medicines in the areas of vaccines, pain, inflammation, anti-infectives and oncology. The two businesses also feature an established products portfolio of more than 600 branded and generic products.
The fastest growth sector within emerging markets is the off-patent segment driven by the demographics and rising economic power in many of these markets. In fact, by 2020 off-patent medicines and their generic equivalents are estimated to account for more than 50 percent of the global pharmaceutical market.
Our footprint in the emerging markets covers key growth countries including Brazil, Russia, India, China, Mexico and Turkey. In these countries and dozens of others in emerging markets, we are dedicated to meeting the diverse medical needs of patients in an innovative, socially responsible and commercially viable manner.
2010 Highlights
-
Enbrel is now available in China for the treatment of rheumatoid arthritis and ankylosing spondylitis. The highly successful medication is Pfizer's first biologic in China.
-
We have acquired a 40 percent stake in Teuto (Laboratório Teuto Brasileiro S.A.), a Brazilian generics firm, greatly enlarging our footprint in a key high-growth market.
-
Pfizer's agreement with Biocon, the Indian biotech firm, over time is adding a key line of biosimilars for treating diabetes to the portfolio.
-
We launched the pneumococcal vaccine Prevenar 13 for infants and young children in 31 emerging markets, including the priority markets of India and Turkey.
